.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The Marengo Asia Hospitals investment landscape is set for a significant shift as the healthcare provider looks to raise ₹500 crore. This capital infusion involves selling a 10% stake to external investors, including pension funds and sovereign wealth funds. Consequently, the company aims to establish a clear valuation benchmark of approximately ₹5,000 crore. Notably, the chain reported a robust revenue of ₹1,200 crore for the financial year 2025-26.
The founding investors, including Samara Capital and the promoter families of Godrej and Havells, initially built the network through a strategic aggregation model. Specifically, they began by rebranding QRG Hospital in Faridabad and co-opting CIMS Hospital in Ahmedabad. Furthermore, the group recently acquired Sunshine Global Hospitals in Gujarat. These bold moves have transformed the entity into a major multispecialty player in the Indian healthcare market. Therefore, the upcoming stake sale represents a pivotal moment for its future scaling efforts.
The company currently operates a network of eight hospitals with a total capacity of 2,500 beds. Moreover, its presence extends across the National Capital Region, Rajasthan, and Gujarat. In a notable international move, the group also established operations in Saudi Arabia. Additionally, they have earmarked funds for further acquisitions in Maharashtra and Rajasthan. Avendus Capital is managing the stake sale process to ensure a diverse investor profile. These strategic expansions reflect the chain's commitment to high-end tertiary care.
Q1: What is the current bed capacity of Marengo Asia Hospitals?
The hospital chain currently operates a total capacity of 2,500 beds across eight hospitals in India and Saudi Arabia.
Q2: Who are the primary investors in the Marengo Asia network?
The company is backed by the private equity firm Samara Capital, alongside the family offices of the Godrej Group and Havells India promoters.
Q3: Which regions are targeted for future hospital acquisitions?
Marengo Asia Hospitals has specifically earmarked funds for new acquisitions in Rajasthan and Maharashtra to further expand its domestic footprint.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Marengo Asia Hospitals seeks ₹500 crore via a 10% stake sale to expand its 2,500-bed network across India and Saudi Arabia....
6 months ago
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today
In high-risk pulmonary embolism complicated by severe anemia and active uterine bleeding, systemic thrombolysis is contraindicated. Large-bore aspiration thrombectomy provides rapid hemodynamic rescue without fibrinolysis, supported by inferior vena cava filter placement and multidisciplinary critical care.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
